| Date | Title | Description |
| 20.07.2023 | Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis | Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local treatment
Mage Bio... |
| 17.03.2023 | TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023 | Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner... |
| 23.02.2023 | TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders | Montreal, Canada / Munich, Germany – 23 February 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced the promotion of Dr. Valentina Agosto... |
| 21.02.2023 | Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ | Montréal, Québec, February 21, 2023 – Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a follow-on investment by TVM Capital Life Science (“TVM”) through its fund TVM Life Science Innovation I SCSp and ... |
| 08.02.2023 | TVM Capital Life Science Announces Creation of LAmAb Biologics to Develop Innovative Preventative Therapy for Allergy Patients | LAmAb Biologics to develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases
LAmAb Biologics is the 9th early-stage or product focused company (PFC) investment for TVM Life Scie... |
| 01.02.2023 | TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc. | Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund
Recurv is developing novel taxane, RP-001, against solid tumors
RP-001 delivered in nano-emulsion formulation, focusing drug... |
| 18.12.2022 | TVM Capital Winter Conference | Dear Friends and Partners of TVM Capital Life Science.
We have decided to cancel the 2023 TVM Winter Conference in Kitzbuehel.
The decision to cancel our 2023 Winter Conference was not easy, but the health and safety of our guests are of ... |
| 01.08.2022 | Panthera D-SAD Classic oral appliance now eligible for Medicare reimbursement | Quebec, Canada, July 28, 2022. Panthera Dental (Quebec, Canada), a global leader in CAD/CAM implant solutions and dental sleep appliances, today announced they have received notification from PDAC that the Panthera D-SAD Classic can be bill... |
| 23.06.2022 | Kent Imaging Recognized as Most Innovative Medical Imaging Technology Developer in Canada | SnapshotNIR is enabling clinicians to drive better outcomes in wound care, limb preservation, and surgery, with its diagnostic-driven imaging technology.
NEWS PROVIDED BY Kent Imaging Inc. June 21, 2022, 16:20 GMT
Kent’s CEO, Pierre Lemir... |
| 29.03.2022 | Egg Medical hatches technology to shield health care workers from radiation | The Arden Hills company has landed $13 million in financing.
By Burl Gilyard Star Tribune MARCH 27, 2022 — 2:00PM
A Twin Cities medtech startup, Egg Medical Inc., is building up sales of a new product called the EggNest that’s overlaid on... |
| 15.03.2022 | Egg Medical hatches $13M VC funding |
March 4, 2022
By Annette Boyle
Egg Medical Inc. secured a $13 million investment from TVM Capital Life Science to solve the Humpty-Dumpty problem that plagues interventional cardiology – the scattering of radiation during X-ray guided p... |
| 03.03.2022 | Egg Medical, Inc., Closes on $13 million Financing |
Egg Medical, Inc., Closes on $13 million Financing
Arden Hills, MN (March 3rd, 2022) — Egg Medical, Inc., a medical device company commercializing technologies to reduce scatter radiation exposure during interventional angiographic proce... |
| 08.02.2022 | CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO | CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 08, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, to... |
| 01.02.2022 | CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board | CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 1, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, tod... |
| 01.02.2022 | CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan | CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 1, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, tod... |
| 01.02.2022 | CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer | CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 1, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, tod... |
| 18.01.2022 | TVM Capital Life Science promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner | Munich, Germany / Montreal, Canada – 12 January 2022 – TVM Life Science (“TVM”),
a leading International Life Sciences Venture Capital firm, today announces the formal
promotion of Dr. Sascha Berger and Dr. Alain Thibault to General Partner... |
| 13.01.2022 | Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies | Luxembourg, January 13th, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA.
Auricula Biosciences plans to develop a first-in-cl... |
| 22.11.2021 | Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update | NEWTON, MA – Nov. 19, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet me... |
| 16.11.2021 | Nekonal and TVM Capital Life Science Announce Creation of T7 Therapeutics to Develop Innovative Therapy for Patients with Auto-immune diseases | Luxembourg, November 15th, 2021 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing T7 Therapeutics, Inc., a company based in Wilmington, Delaware, USA.
T7 Therapeutics plans to develop, a first-in-class mono... |
| 16.11.2021 | Kent Imaging – Setting A New Global Standard in Advanced Tissue Assessment | November 16, 2021
Kent Imaging is a market leader in light-based tissue assessment diagnostic devices. The company designs and manufactures imaging technology that supports real-time decision-making in wound care, vascular and surgical spe... |
| 08.10.2021 | Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation | Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036
NEWTON, MA and GENEVA, SWITZERLAND – October 7, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) ... |
| 08.10.2021 | CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand,... |
| 15.07.2021 | Rapid Micro Biosystems Announces Pricing of Initial Public Offering | Source: Rapid Micro Biosystems, Inc.
July 14, 2021 21:30 ET
LOWELL, Mass., July 14, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“RapidMicro”), an innovative life sciences technology company providing mission critica... |
| 27.05.2021 | Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
Following Pre-NDA Meeting with FDA | NEWTON, MA and GENEVA, SWITZERLAND – May 25, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening dis... |
| 25.03.2021 | COVID Innovations March 25th, 2021 | Author: Dr. Linda Morrow – March 25th, 2021
Imagine a pandemic without having to shut down our lives. Imagine governments and industry working cooperatively to develop diagnostic and vaccine platforms ready to be deployed. Imagine scientis... |
| 22.03.2021 | Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Diseas... | Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights
ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021
GENEVA, SWITZERLAND and NEWTON, MA – March 22, 2021 – RELIEF ... |
| 04.03.2021 | Access Vascular, Inc. Secures $20 Million in Series B Financing | Bedford, MA – 03 March, 2021-
Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. TVM Capital Life Science led the round with a... |
| 25.02.2021 | Kent’s deal with Net Health to expand Snapshot’s footprint | By David Godkin, Staff Writer
TORONTO – Think of it. More than 14,000 facilities boasting 98% of the largest hospital chains across the U.S., two-thirds of skilled nursing facilities and hospice organizations and doctors’ offices. It’s that... |
| 01.02.2021 | TVM Life Science Innovation II SCSp Announces Investment in Sarkana Pharma, Inc. | Luxembourg, February 1st, 2021 –TVM Life Science Innovation II SCSp today announced the fund’s investment establishing Sarkana Pharma, Inc., a company based in Wilmington, Delaware.
Sarkana Pharma, Inc. plans to develop, to proof-of-concep... |
| 01.02.2021 | TVM Life Science Innovation II SCSp Announces Investment in Vespina Lifesciences Inc. | Luxembourg, February 1st, 2021 – TVM Life Science Innovation II SCSp today announced the Fund’s investment establishing Vespina Lifesciences Inc., a company based in Newark, Delaware.
Vespina Lifesciences Inc. plans to develop to proof-of-... |
| 19.01.2021 | TVM Life Science Innovation II SCSp Announces Investment in ImmunoRx Pharma, Inc. | Luxembourg, January 19th, 2021 –TVM Life Science Innovation II SCSp today announced the fund’s investment establishing ImmunoRx Pharma, Inc., a company based in Wilmington, Delaware. ImmunoRx Pharma, Inc. plans to develop, to proof-of-conce... |
| 14.01.2021 | Kent Imaging Inc. is accelerating its growth through a US$15M investment by TVM Life Science Innovation II SCSp | CALGARY, AB, CANADA, January 13, 2021
/EINPresswire.com/ — Kent Imaging, an innovator in the tissue imaging market, announced today its partnership with TVM Life Science Innovation II SCSp to accelerate the global commercialization of its ... |
| 07.01.2021 | Emovi and SIAwards: 2nd interview on KneeKG and knee pain | The interview was live just before the award to Lebron James!
The interview also presents Dr Michael Suk, orthopedic surgeon and clinical expert Luis Zuniga, PT owner, talking about the KneeKG.
Here is the link:
https://www.emovi.ca/ldt-... |
| 13.11.2020 | Dentsply Sirona and Panthera Dental announce collaboration: fully digital workflow for custom-made sleep devices | (Charlotte/Quebec, November 12, 2020)
Dentists now have the opportunity to use Primescan in a new area of application: Obstructive Sleep Apnea (OSA) and snoring, which affects up to 3.61 billion people worldwide and is a growing market. De... |
| 27.10.2020 | TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm’s history | Munich/Montreal: October 27, 2020 – TVM Capital Life Science, one of the leading life sciences venture capital firms in North America and Europe, today announced the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI ... |
| 22.10.2020 | CENTOGENE Announces Leadership Transition | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, October 20, 2020
(GLOBE NEWSWIRE) —
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable ... |
| 15.07.2020 | CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 9, 2020
(GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and gen... |
| 10.07.2020 | CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable infor... |
| 08.04.2020 | Centogene öffnet seine Labore für Coronatests | Verantwortung in Krisenzeiten: Ein Rostocker Unternehmen, das sonst seltenen Krankheiten auf der Spur ist, öffnet seine Labore für lebensrettende Coronatests. Bis zu 10.000 Abstriche können pro Tag untersucht werden. (Auf KfW Stories veröff... |
| 03.04.2020 | Panthera employees in Quebec City have been hard at work manufacturing various prototypes of equipment designed to protect caregivers | (Montreal, March 24, 2020) Across Quebec, 3D printing companies are active in the fight against the Coronavirus.
Stéphane Blais
The Canadian Press
They make prototypes of masks and visors; valves; devices for opening doors without using ... |
| 24.03.2020 | Centogene Announces Commencement of Testing for COVID-19 | Cambridge, MA, USA & Rostock/Berlin, Germany, March 18, 2020 (GLOBAL NEWSWIRE) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable informat... |
| 04.02.2020 | La Presse: “Laurent Duvernay-Tardif’s knees at their best thanks to a “knee kinesiography with KneeKG” by EMOVI | “Unless he is injured during the game on Sunday, Laurent Duvernay-Tardif will be solid on both knees when he blocks to protect Patrick Mahomes, the Kansas City Chiefs quarterback, in order to allow his team to win the Super Bowl; and it is ... |
| 15.11.2019 | CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc. | Accelerating new rare disease therapies through collaboration agreement
Cambridge, MA, USA & Rostock/Berlin, GERMANY,13 November 2019 – CENTOGENE (Nasdaq: CNTG),commercial-stage company focused on rare diseases that transforms real-wor... |
| 08.11.2019 | Centogene AG Rings The Nasdaq Stock Market Closing Bell in Celebration of its IPO | - |
| 29.10.2019 | CENTOGENE Announces Proposed Initial Public Offering of Common Shares | October 28, 2019 at 8:53 AM EDT
CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) — Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical ... |
| 18.10.2019 | Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS | Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter Phase 1 clinical trial t... |
| 14.10.2019 | Lilly’s REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval | The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades
INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced... |
| 02.10.2019 | Emovi Announces Results of Clinical Trial to Manage Knee Osteoarthritis with KneeKGTM | Results demonstrates that use of KneeKG in patients with osteoarthritis reduces pain, improves patient quality of life, and may reduce need for unnecessary surgery.
Montreal, Quebec (October 1st, 2019) Today, Emovi, Inc. announces positive... |
| 25.09.2019 | Proteon Therapeutics and ArTara Therapeutics Agree to Combine | September 23, 2019
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders
$42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors
WA... |
| 17.09.2019 | BIO Deutschland – Biotechnologie-Branchenverband wählt Dr Hubert Birner in den Vorstand | Berlin (17. September 2019) – Der Branchenverband der Biotechnologie-Industrie, BIO Deutschland e. V., hat gestern während der 16. ordentlichen Mitgliederversammlung in Berlin einen neuen Vorstand für die nächsten zwei Jahre gewählt.
Die z... |
| 24.06.2019 | We are very proud to have won the Deal of The Year Award 2019! | The Canadian Venture Capital and Private Equity Association (CVCA) announced the winners of its annual Deal of the Year awards during its annual Invest Canada 19 conference taking place in Vancouver.
TVM Capital Life Science won in the ven... |
| 28.05.2019 | CENTOGENE Welcomed Germany’s Chancellor Dr. Angela Merkel | CENTOGENE welcomed Germany’s Chancellor Dr. Angela Merkel on May 23, 2019 to its headquarters together with Manuela Schwesig, Minister-President of Mecklenburg-Vorpommern. The visit focused on explaining CENTOGENE’s capabilities in the fiel... |
| 02.04.2019 | CENTOGENE announces the appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman | Rostock/Berlin, Germany, 2 April, 2019 – CENTOGENE announced today that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.
Dr. Flemming ... |
| 04.03.2019 | Emovi is accelerating its growth through a 15M$ Series C investment led by TVM Capital Life Science | Photo: Emovi
MONTREAL, March 4, 2019 /CNW Telbec/ – Emovi announced today its partnership with TVM Capital Life Science and co-investors StandUp Ventures and Desjardins Capital to support its global commercial activities. This 15M$ Series ... |
| 02.01.2019 | Please use our dedicated page for Funding Requests! | We have added a new page to the website to ensure timely processing of your funding requests. Please use this dedicated page to file your deals with us: http://tvmlifescience.de/funding-request/
|
| 17.10.2018 | 1. Tiroler Biotech Konferenz an der UMIT: „Where Life Science Meets Capital“ | Einzigartige Initiative von privatem Risikokapital und öffentlicher Hand unter Beteiligung des Landes Tirol und seinen Universitäten , der Hypo Tirol Bank sowie dem Innovationsspezialisten Cemit.
Mit der 1. Tiroler Biotech Konferenz an der... |
| 03.10.2018 | CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials | CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients.
CENTOGENE will conduct a targeted globa... |
| 07.06.2018 | F-star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F-star Gamma | Cambridge, UK, 30 May 2018 – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies, announced today that its partner Denali Therapeutics (NASDAQ: DNLI) (Denali) has chosen to exercise early its option to ... |
| 14.05.2018 | Lilly to Acquire AurKa Pharma | Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types
INDIANAPOLIS, IN – Eli Lilly and Company (NYSE:LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established ... |
| 08.05.2018 | Rapid Micro Biosystems Secures $60 Million In Equity Financing | Investment to Accelerate Company’s Continued Global Commercial Expansion and Product Innovation
Lowell, MA – May 2, 2018 – Rapid Micro Biosystems, the leading provider of automated, growth-based, rapid microbial detection technology for th... |
| 13.04.2018 | Deinove To Acquire Biovertis/Morphochem | Deinove Gains Access to Biovertis/Morphochem’s Lead Compound MCB3837 for the Potential Treatment of Clostridium Difficile Infections (CDI)
Vienna/Munich, 13 April 2018: Biovertis AG, Vienna and TVM Capital Life Science, Munich today announ... |
| 19.03.2018 | Prof. Arndt Rolfs joins newly formed “Global Commission to End the Diagnostic Odyssey” | Prof. Arndt Rolfs, CENTOGENE AG, has joined newly formed “The Global Commission to End the Diagnostic Odyssey for Children”, a dedicated group of technology innovators, patient advocates, healthcare providers and researchers.
The commissio... |
| 13.11.2017 | Norgine Ventures completes €2 million financing with pritidenta | LONDON, UK. 7 November 2017, 08:35 AM GMT. Norgine Ventures announced today that it has provided financing of up to €2 million to pritidenta® GmbH, a company based in Leinfelden-Echterdingen, Germany, which develops and sells innovative mat... |
| 05.11.2017 | Meet us at BIO-EUROPE! |
We are happy and honored sponsors of this year’s BIO-EUROPE in Berlin, taking off on Monday, November 6, 2017. Do not miss our panel discussion moderated by Managing Partner Dr. Hubert Birner:
Level 3, Room M4
The pediatric disease area... |
| 25.10.2017 | TVM Capital Life Science exits invendo medical GmbH | Ballerup, Denmark and Kissing, Germany, October 25, 2017 – Today, Ambu A/S – a leader in the development, manufacturing and marketing of single-use devices for hospitals (NASDAQ OMX Copenhagen: AMBU)–has acquired invendo medical GmbH. inven... |
| 04.10.2017 | Panthera Dental is accelerating its growth through investments by TVM Life Science Ventures VII and Emerillon Capital | Quebec City, October 3, 2017
Panthera Dental announced today itspartnership with TVM Life Science Ventures VII and Emerillon Capital venture capitals in order to support its export activities.
With this financial assistance, Panthera Dent... |
| 20.09.2017 | TVM Capital Life Science hosts its 6th annual Life Science Conference in Montreal | Montreal, September 19, 2017
TVM Capital Life Science convened its 6th annual Autumn Conference in Montreal yesterday, with more than 200 international attendees from Asia, the United States, Europe and Canada who networked with senior dec... |
| 04.07.2017 | Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement | Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need
Concurrent financing of $15.7 million from Ace... |
| 23.06.2017 | Proteon Therapeutics Announces $22.0 Million Private Placement | Provides Sufficient Cash into Q4 2019
WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) — Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney an... |
| 13.06.2017 | CENTOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine | Rostock/Berlin, 13.06.2017 – CENTOGENE AG, a worldwide leader in the field of genetic diagnostics for rare diseases, announced today its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deuts... |
| 04.06.2017 | Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase | WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced th... |
| 17.05.2017 | Attraktiv für Investoren! Individualisierte Medizin ist schon lange grundlegend für die erfolgreiche Behandlung von Patienten | Eine große Zahl von VC Investitionen im Life Science Bereich und deren Innovation sind implizit Investitionen in personalisierte Medizin oder Precision Medicine. Das können Beteiligungen an einer Plattform sein, an einem neuen Target und ei... |
| 09.05.2017 | NOXXON PHARMA secures a private placement of 1 million Euro and additional financing of up to 10 million Euro through convertible notes with share subscription warrants attached to finance further cli... | Berlin, Germany, May 2, 2017 – NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, today announced:
As part of this financing of th... |
| 23.03.2017 | Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid | $960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-state pipeline
INDIANAPOLIS, IN and CAMBRIDGE, MA, January 18, 2017– Eli Lilly and Company (NYSE:LLY) and C... |
| 09.01.2017 | leon Appoints Pharma Expert Michael Mehler as Chief Executive Officer | leon nanodrugs GmbH appoints pharma expert Michael Mehler, Sc.D. as new CEO of the Munich based company and its U.S. subsidiary leon-nanodrugs Inc, effective today. He succeeds Dr. Theron (Ted) Odlaug who will continue to serve the company ... |
| 07.12.2016 | Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS | Schlieren, Switzerland, and Munich, Germany, December 07, 2016 / B3C newswire / — Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in AL-S Pharma AG, a company based in S... |
| 05.12.2016 | NOXXON PHARMA ANNOUNCES NEW PRECLINICAL DATA SHOWING SYNERGY OF LEAD COMPOUND NOX -A1 2 WITH NATURAL KILLER (NK) CELL MEDIATED THERAPIES | Poster Title: CXCL12 Inhibition by NOX-A12 (Olaptesed Pegol) Synergizes With the ADCC Activity of CD20 Antibodies by Increasing NK Cell Infiltration in a 3D Lymphoma Model
Authors: Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Va... |
| 05.12.2016 | Pfizer Ventures and TVM Life Science Ventures VII Announce Additional Investment in Ixchelsis Ltd. | London, UK, December 05, 2016 / — Pfizer Venture Investments (PVI) and TVM Life Science Ventures VII today announced that they are making an additional $12M investment in Ixchelsis Ltd, a start-up company based at Discovery Park, Sandwich, ... |
| 04.11.2016 | Albireo Completes Transaction with Biodel to Create Publicly Traded Company Focused on Orphan Pediatric Liver Diseases | November 3, 2016
— Albireo Pharma, Inc. to trade on The NASDAQ Capital Market under symbol “ALBO” —
— Company to develop novel bile acid modulators to treat orphan pediatric liver diseases, other liver and gastrointestinal diseases —
Bos... |
| 04.11.2016 | Funding the funders: Insight into the funders of VC healthcare investment – Dr. Hubert Birner moderates@BIOEurope 2016 |
Cologne Conference Center
Date: November 7, 2016
Time: 16:00 – 17:00
Stream: Main agenda, Level 2, Room 3
Venture capitalists are the public face of innovative healthcare funding but they also go through fundraising rounds. Who are th... |
| 19.09.2016 | TVM Life Science Ventures VII Announces Investment in AurKa Pharma Inc. | Montréal, Québec, September 19th, 2016 –TVM Life Science Ventures VII today announced the fund’s twelfth investment establishing AurKa Pharma Inc., a company based in Montréal, Québec. AurKa Pharma Inc. plans to develop, to proof-of-concept... |
| 07.09.2016 | invendo medical Announces FDA Clearance of the invendoscopy E200 System –Including the First and Only Sterile, Single-use Endoscope For Colonoscopies | A Simple, Safe and Effective Solution to the Challenges of Cross-Contamination and Infection Control
New York, USA and Kissing, Germany, September 7, 2016 – invendo medical GmbH, a leading developer and distributor of sterile, single-use a... |
| 06.09.2016 | CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine | Cambridge, MA, September 6, 2016 — CoLucid Pharmaceuticals, Inc., a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today that its Phase 3 p... |
| 10.08.2016 | CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights | CAMBRIDGE, MA – August 10, 2016 – CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the quarter ended June 30, 2016.
Corporate Highlights
On June 7, CoLucid announced that the last patient has... |
| 25.07.2016 | FDA grants QIDP and Fast Track Designations to MCB3837, Morphochem’s novel intravenous antibacterial to treat C. difficile infections | Munich (Germany), July 25, 2016 — Morphochem, a clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous (IV) antibacterial product candidate MCB3837 as ... |
| 22.06.2016 | Morphochem’s Investigational New Drug (IND) application accepted by the FDA – Novel antibacterial for intravenous treatment of Clostridium difficile infections (CDI), MCB3837/MCB3681, can now move int... | Munich, Germany, June 22, 2016 — Morphochem, a private clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for the company’s nov... |
| 21.06.2016 | TVM Life Science Ventures VII Announces Investment in Mediti Pharma Inc. for the Development of a Novel Treatment for Alzheimer’s Disease Psychosis | Montréal, Québec, June 20, 2016 – TVM Life Science Ventures VII closed the fund’s eleventh investment, establishing Mediti Pharma Inc., a company based in Montréal, Québec. Mediti Pharma Inc. is developing a compound, MP-101, originally dis... |
| 09.06.2016 | CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 | CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) — CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, ann... |
| 27.05.2016 | Biodel Inc. and Albireo Limited Agree to Combine | May 24, 2016
Conference call on Wednesday, May 25, 2016 at 8:30 a.m. ET
Danbury, CT and Boston, MA, May 24, 2016 – Biodel Inc. (Nasdaq: BIOD) and Albireo Limited, a privately held biopharmaceutical company, today announced that the compan... |
| 27.05.2016 | CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine | CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) — CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing oral lasmiditan for the acute treatment of migraine in adults, announced today that the f... |
| 14.04.2016 | Esperas Pharma Inc. will begin clinical development of a new anti-cancer product at major Montreal hospitals | Montréal, Québec, April 11 2016 – Esperas Pharma Inc. (“Esperas”) today announced the initiation of a project to develop a new oral anticancer agent called ESP-01, in partnership with Quebec Clinical Research Organization in Cancer (Q-CROC)... |
| 02.03.2016 | CoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTAN | CAMBRIDGE, MA – March 1, 2016 – CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine, has announced t... |
| 01.02.2016 | TVM Life Science Ventures VII Announces Investment in Modulate Therapeutics Inc. for the Development of a Novel Immune-Oncology Nanomedicine | Montréal, Québec, February 1st, 2016 –TVM Life Science Ventures VII today announced the fund’s ninth investment – establishing Modulate Therapeutics Inc., a company based in Montréal, Québec. Modulate Therapeutics Inc. plans to develop, to ... |
| 25.01.2016 | TVM Capital Life Science portfolio company Ixchelsis Ltd announces positive clinical Proof of Concept results for IX-01 in treating premature ejaculation | January 25, 2016 -Sandwich, UK. – Ixchelsis Ltd, a UK based biotech company, announced today that it has achieved positive clinical proof of concept (POC) for IX-01, its oral oxytocin receptor antagonist being developed for the treatment of... |
| 11.12.2015 | Watch the BIO-Europe Session on external innovation strategies | We are proud to have hosted one of the best attended panel discussions at BIO-Europe this year, moderated by Dr. Hubert Birner, Managing Partner.
Watch the session here:
http://bit.ly/1Qg5fHn
|
| 23.09.2015 | Quebec Minister of finance, Carlos J. Leitao, held the Keynote at TVM capital life science autumn conference venture capital IN life sciences | Montréal, Québec, September 22st, 2015 –TVM Capital Life Science yesterday held its 4th annual TVM Capital Autumn Conference which hosted more than 170 participants from around the globe including Asia, MENA, Europe, the United States and C... |
| 27.07.2015 | leon-nanodrugs GmbH raises EUR 18.5 million in Series A financing | TVM Capital Life Science leads international syndicate of investors – an additional EUR 3 million investment is expected later in 2015
Munich, 27 July 2015 — leon nanodrugs GmbH today announced that it completed the first closing of its Se... |
| 17.07.2015 | Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 | Fully Personalized Immunotherapy is Being Evaluated in Combination With Standard Targeted Therapy for the Treatment of Newly Diagnosed Metastatic Renal Cell Carcinoma
DURHAM, N.C., July 15, 2015 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (... |
| 15.06.2015 | Probiodrug receives 2015 European Mediscience Award for Best Technology | HALLE/SAALE, Germany, 12 June 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces it has been awarded Best Technology at last night’... |
